Updated Clinical Data from Combination of Margetuximab and Pembrolizumab in Gastric Cancer Presented at 2019 ASCO Gastrointestinal Cancers Symposium
“We continue to be very encouraged by the tolerability and antitumor activity of margetuximab with an anti-PD-1 mAb, an investigational, chemotherapy-free approach... Read More
